Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

Name: Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
License: Public Domain

First Affiliated Hospital of Wannan Medical College

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

small cell lung cancer extensive stage, resistance to immunotherapy

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 249605
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.